The DOI matches its Crossref record; 10 of the 11 references it cites were found in a registry or an index, and 1 are not checked yet.
Correlation of IL-31 serum levels with severity of atopic dermatitis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-31 is a prominent pruritogenic cytokine produced by infiltrating TH2 cells in AD and correlates with disease severity97,184,185.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [185]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,597
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice
Dillon, S. R., Sprecher, C. A., Hammond, A. J., Bilsborough, J., Rosenfeld-Franklin, M., Presnell, S., Haugen, H. S., Maurer, M. F., Harder, B., Johnston, J. V., et al. (2004) · Nature Immunology · doi:10.1038/ni1084 · Cited by 1,018
IL-31: A new link between T cells and pruritus in atopic skin inflammation
Sonkoly, E., Müller, A., Lauerma, A., Pivarcsi, A., Soto, H., Kemény, L. V., Alenius, H. T., Dieu‐Nosjean, M., Meller, S., Rieker, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.033 · Cited by 1,000
Neis, M. M., Peters, B., Dreuw, A., Wenzel, J., Bieber, T. R. M., Mauch, C., Krieg, T., Stanzel, S. F., Heinrich, P. C., Merk, H. F., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.07.015 · Cited by 377
Bilsborough, J., Leung, D. Y. M., Maurer, M. F., Howell, M. D., Boguniewcz, M., Yao, L. Y., Storey, H., LeCiel, C., Harder, B., & Gross, J. A. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.10.046 · Cited by 368
Pathophysiology of pruritus in atopic dermatitis: an overview
Ständer, S., & Steinhoff, M. S. (2002) · Experimental Dermatology · doi:10.1034/j.1600-0625.2002.110102.x · Cited by 250
Self-citationInvolvement of IL‐31 on scratching behavior in NC/Nga mice with atopic‐like dermatitis
Takaoka, A., Arai, I., Sugimoto, M., Honma, Y., Futaki, N., Nakamura, A., & Nakaike, S. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00405.x · Cited by 152
Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis
Takaoka, A., Arai, I., Sugimoto, M., Yamaguchi, A., Tanaka, M., & Nakaike, S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.04.040 · Cited by 120
Boguniewicz, M., Schmid‐Grendelmeier, P., & Leung, D. Y. M. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.04.044 · Cited by 86
A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema
Schulz, F., Marenholz, I., Fölster‐Holst, R., Chen, C. I.-U., Sternjak, A., Baumgrass, R., Esparza-Gordillo, J., Grüber, C., Nickel, R. G., Schreiber, S., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.07.065 · Cited by 81
Cited by
Sorted by citations
Items 201–299 of 299
Saintive, S., Abad, E. D. D., Ferreira, D. D. C., Stambovsky, M., Cavalcante, F. S., Gonçalves, L. S., Vidal, F., & dos Santos, K. R. N. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0081 · Cited by 11
Pathogenese der Prurigo nodularis
Raap, U., & Günther, C. (2014) · Der Hautarzt · doi:10.1007/s00105-014-2754-y · Cited by 11
Self-citationNew Methods of Prevention and Treatment of Allergic Diseases
El‐Qutob, D. (2012) · Recent Patents on Inflammation & Allergy Drug Discovery · doi:10.2174/187221312798889257 · Cited by 11
“In another study, the authors found a correlation of IL-31 serum levels with severity of intrinsic and extrinsic type of atopic dermatitis[78].”
BackgroundInteraction of S100A6 Protein with the Four-Helical Cytokines
Kazakov, A. S., Deryusheva, E. I., Rastrygina, V. A., Sokolov, A. S., Permyakova, M. E., Андреевна, Л. Е., Uversky, V. N., Permyakov, E. A., & Permyakov, S. E. (2023) · Biomolecules · doi:10.3390/biom13091345 · Cited by 10
Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis
Komori, T., Hisaoka, T., Kotaki, A., Iwamoto, M., Miyajima, A., Esashi, E., & Morikawa, Y. (2023) · The FASEB Journal · doi:10.1096/fj.202301529r · Cited by 10
“10,11 The expression of IL-31 is increased in the lesional skin of the patients with AD 12 as well as mouse models of AD, such as NC/ Nga mice.”
BackgroundAnti-atopic dermatitis effect of fraxinellone via inhibiting IL-31 in vivo and in vitro
Yang, N., Deng, J., Xu, H., Dai, H., Han, J., Shao, H., & Liu, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35391 · Cited by 10
“Studies have shown that serum levels of IL-31 are positively correlated with the severity of AD [8].”
BackgroundSasaki, W., Saito, R., Suzuki, K. M., Watanabe, D., Minami‐Hori, M., Kamada, H., Amano, H., Uchiyama, A., Motegi, S., Kamura, M., et al. (2025) · The Journal of Dermatology · doi:10.1111/1346-8138.17877 · Cited by 10
Olszewska, B., Sokołowska‐Wojdyło, M., Lakomy, J., & Nowicki, R. J. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.96260 · Cited by 12
“Four-helix bundle cytokine, interleukin-31 (IL-31), is a non-histamine pruritogen that is proven to be correlated with pruritus in atopic dermatitis [7, 8].”
BackgroundBoyvadoğlu, C., Ulusal, H., Tayşi, S., Yavuz, G. Ö., Yavuz, İ. H., Korkmaz, P., & Inaloz, H. S. (2023) · Mediators of Inflammation · doi:10.1155/2023/8087274 · Cited by 9
“It has been suggested to be a major dermal pruritogen because it has been shown to play a very important role in itching in patients with atopic dermatitis [8].”
BackgroundThe ontogenesis and heterogeneity of basophils
Park, J., & Kang, S. (2024) · Discovery Immunology · doi:10.1093/discim/kyae003 · Cited by 10
“This is mediated by IL-31-dependent neuroimmune communication [15, 16] involving basophils [17].”
BackgroundLi, Q., Tang, T., Zhang, P., Liu, C., Pu, Y., Zhang, Y., Song, H., Wang, Y., Song, Y., Su, M., et al. (2017) · Familial Cancer · doi:10.1007/s10689-017-0060-4 · Cited by 9
New insight of itch mediators and proinflammatory cytokines in epidermolysis bullosa
Nguyen, H. H., Shinkuma, S., Hayashi, R., Katsumi, T., Nishiguchi, T., Natsuga, K., Fujita, Y., & Abe, R. (2022) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12230 · Cited by 9
Aktuelles zur kutanen Neurobiologie von Pruritus
Raap, U., Papakonstantinou, E., Metz, M., Lippert, U., & Schmelz, M. (2016) · Der Hautarzt · doi:10.1007/s00105-016-3838-7 · Cited by 9
“» BDNF ist bei atopischer Dermatitis im Serum erhöht und korreliert mit der Krankheitsschwere Neben BDNF können eosinophile Granulozyten auch NGF freisetzen.”
BackgroundInfluentialSelf-citationSodium hyaluronates applied in the face affects the diversity of skin microbiota in healthy people
He, C., Yue, Y.-X., Li, R., Huang, Y., Shu, L., Lv, H., Wang, J., & Zhang, Z. (2023) · International Journal of Cosmetic Science · doi:10.1111/ics.12845 · Cited by 10
“epidermidis can express a soluble phenol molecule and exert an effect similar to antimicrobial peptides, which may be related to its protective effects [53].”
BackgroundStull, C. M., Tey, H. L., & Yosipovitch, G. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-2991 · Cited by 9
“Increased IL-31 expression has also been detected in other pruritic conditions including atopic dermatitis, prurigo nodularis, and cutaneous T-cell lymphoma (8).”
BackgroundIncreased tissue expression of IL-31 in patients with psoriasis
Wongjirattikarn, R., Chaisuriya, N., Chaowattanapanit, S., Ungarreevittaya, P., Poosekeaw, P., Winaikosol, K., Choonhakarn, C., Julanon, N., Utchariyaprasit, E., & Sawanyawisuth, K. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156531 · Cited by 8
A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularis
Nilforoushzadeh, M. A., Heidari, N., Ghane, Y., Heidari, A., Hajikarim‐Hamedani, A., Hosseini, S., Jaffary, F., Nobari, M. N., Tavakolzadeh, P., & Nobari, N. N. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01436-9 · Cited by 8
“This itching mediator acts by binding to a heterodimeric receptor with two subunits, including IL-31 receptor A (IL-31RA) and OSM receptor β (OSMRβ), and conducting the signal via JAK–signal transducer and activator of transcription 3 (JAK–STAT3) pathway (Datsi et al. 2021; Raap et al. 2008).”
Cytokine Profiles of Chronic Urticaria Patients and the Effects of Omalizumab Treatment
Bostan, Ö. C., Damadoğlu, E., Sarac, B. E., Kilic, B., Şahiner, Ü. M., Karaaslan, Ç., Karakaya, G., & Kalyoncu, A. F. (2023) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1304a272 · Cited by 8
“Statistical significance in ESR Therefore, pharmacological inhibition of the interaction between TSLP and its receptor or antibody-mediated TSLP neutralization was discussed to be a possible option in the treatment of CSU patients [35].”
BackgroundArtusa, S., Mazzuca, G., PIACENTINI, G. L., Castagnoli, R., Marseglia, G. L., Pietrobelli, A., & Pecoraro, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094778 · Cited by 12
“Patients with atopic dermatitis may also experience mood disorders, such as relationship problems, depression, and anxiety, which can further impair the patient’s quality of life and even increase the risk of suicide, highlighting the profound psychological impact of the condition [33].”
BackgroundOlszewska, B., Żawrocki, A., Gleń, J., Lakomy, J., Karczewska, J., Zabłotna, M., Malek, M., Jankau, J. A., Lange, M., Biernat, W., et al. (2021) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.100824 · Cited by 8
“The role of IL-31 and its receptor components (IL-31 RA and OSMR) in pruritus that accompanies AD has been determined by many studies [8, 10, 14, 15, 22] while reports on IL-31’s role in CTCL are scarce and conclusions are rather vague.”
BackgroundDivergent in situ expression of IL ‐31 and IL‐31RA between bullous pemphigoid and pemphigus vulgaris
Ergün, E. Z., Aoki, R., Horváth, O. N., Hartmann, D., Satoh, T. K., Calabrese, L., Aksu, A. E. K., Gürel, M. S., Manav, V., Flaig, M. J., et al. (2023) · Experimental Dermatology · doi:10.1111/exd.14842 · Cited by 7
Raap, U., Kapp, A., Wedi, B., & Ständer, S. (2010) · Der Hautarzt · doi:10.1007/s00105-010-1931-x · Cited by 7
Self-citationFeline Interleukin-31 Shares Overlapping Epitopes with the Oncostatin M Receptor and IL-31RA
Medina‐Cucurella, A. V., Bammert, G. F., Dunkle, W., Javens, C., Zhu, Y., Mutchler, V. T., Teel, J. F., Stein, C. A., Dunham, S. A., & Whitehead, T. A. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00176 · Cited by 7
Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond
David, E., Hawkins, K. A., Shokrian, N., DUCA, E. D., & Guttman‐Yassky, E. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2368192 · Cited by 7
“IL-31 binding to its receptor stimulates Janus kinase (JAK)/STAT and PI3K/AKT pathways, leading to itch sensation [64] and, possibly, promoting the growth of sensory nerves, increasing skin hypersensitivity [65–69].”
BackgroundItch Management: Treatments under Development
Pereira, M. P., & Ständer, S. (2016) · Current problems in dermatology · doi:10.1159/000446046 · Cited by 5
Self-citationNovel therapies and the potential for a personalized approach to atopic dermatitis
Balakirski, G., & Novak, N. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000759 · Cited by 5
“Moreover, serum levels of IL-31 correlate with AD severity [21].”
BackgroundInterleukin antagonists for atopic dermatitis: a new era of therapy
Tsiogka, A., Paschou, E., Koumaki, D., Vakirlis, E., & Gregoriou, S. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2347294 · Cited by 5
Yuta, A., Ogihara, H., Yamanaka, K., Ogawa, Y., Mizutani, H., & Okubo, K. (2012) · Clinical & Experimental Allergy Reviews · doi:10.1111/j.1472-9733.2012.01168.x · Cited by 5
van Santen, S., Out‐Luiting, J. J., Zoutman, W. H., Quint, K. D., Willemze, R., Vermeer, M. H., & Tensen, C. P. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101007 · Cited by 5
Biomarkers for Atopic Dermatitis in Children
Tamagawa‐Mineoka, R. (2016) · Pediatric Allergy Immunology and Pulmonology · doi:10.1089/ped.2016.0703 · Cited by 5
“40,41 However, it has been reported that serum IL-31 levels are not increased in children with AD.”
Ningombam, A., Handa, S., Srivastava, N., Mahajan, R., & De, D. (2021) · Clinical and Experimental Dermatology · doi:10.1111/ced.15032 · Cited by 5
Interleukin‐31: Its Role in Canine Pruritus and Naturally Occurring Canine Atopic Dermatitis
Gonzales, A. J., Humphrey, W. R., Messamore, J. E., Fleck, T. J., Fici, G. J., Shelly, J. A., Teel, J. F., Bammert, G. F., Dunham, S. A., Fuller, T. E., et al. (2013) · doi:10.1002/9781118644317.ch7 · Cited by 5
The search for blood biomarkers useful in treating atopic dermatitis patients
Izuhara, K., Nunomura, S., Nakahara, T., & Onozuka, D. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2438192 · Cited by 5
Pharmacological targeting of allergen-specific T lymphocytes
Tauber, P. A., & Pickl, W. F. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.03.010 · Cited by 4
“IL-31 represents a pruritogenic cytokine [19].”
Nakayama, T., Morimoto, K., Uchiyama, K., Kusahana, E., Washida, N., Azegami, T., Kanda, T., Yoshida, T., & Itoh, H. (2022) · Peritoneal Dialysis International · doi:10.1177/08968608221085432 · Cited by 4
Craig, N., Munguia, N. S., Trujillo, A. D., Wilkes, R., Dorr, M., & Marsella, R. (2023) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.22.12.0588 · Cited by 4
(2015) · Itch & Pain · doi:10.14800/ip.467 · Cited by 4
“Previous studies have shown that IL-31 and its receptors IL-31RA and OSMR are involved in AD, pruritus and dermatitis at the mRNA level [15] .”
BackgroundNeues und Bewährtes zur Therapie des atopischen Ekzems
Fölster‐Holst, R. (2012) · Allergo Journal · doi:10.1007/s15007-012-0391-2 · Cited by 3
Choi, Y., Fan, M., Yu, Y., Wang, X., Tang, Y., & Kim, E. (2020) · Animal Production Science · doi:10.1071/an19500 · Cited by 3
IL-27 as a novel biomarker for pruritus in nodular prurigo and bullous pemphigoid
Wang, Y., Zhang, X., Teng, Y. T., & Shen, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1499868 · Cited by 3
Kaneda, N. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22150 · Cited by 3
Study of serum level of interleukin-31 in patients with uremic pruritus
Yousef, A., Haggag, M., Kora, M. A., Safan, M., & Yasien, H. (2020) · Menoufia Medical Journal · doi:10.4103/mmj.mmj_186_18 · Cited by 3
Biologics for Allergic Dermatologic Diseases
Bilimoria, S. N., & Lio, P. (2020) · Current Allergy and Asthma Reports · doi:10.1007/s11882-020-00923-7 · Cited by 3
Determination of interleukin 31 (IL-31) serum levels in allergic rhinitis patients
Ashari, N. S. M., Amin, S. N. S. M., Hamid, W. Z. W. A., Musa, M., Rahman, A. A., & Mohamad, İ. (2014) · International Journal of Pediatrics and Adolescent Medicine · doi:10.1016/j.ijpam.2014.10.003 · Cited by 3
Determination of Interleukin 31 (IL-31) serum levels according to severity of allergic rhinitis
Ashari, N. S. M., Amin, S. N. S. M., Hamid, W. Z. W. A., Rahman, A. A., & Muhammad, I. (2015) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v14i4.20393 · Cited by 3
Turner, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-29785-9_15 · Cited by 5
Rethinking interleukin-31: A neuroimmune orchestrator of itch beyond Th2 immunity
Irie, H., & Kabashima, K. (2026) · Allergology International · doi:10.1016/j.alit.2026.04.004 · Cited by 4
Zheng, Y., Fan, Z., Zhang, J., Chen, J., Wang, L., Pang, X., Guo, T., Liu, J., Gao, F., & Xiao, H. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.05.013 · Cited by 2
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Merritt, J. R., Moench, I., Pance, K., & Petojevic, T. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch25 · Cited by 2
The Cytokine Network in Pathogenesis of Atopic Dermatitis
Higashi, N. (2017) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.13.8 · Cited by 2
Neurophysiologie des atopischen Pruritus
Meyer, N. H., Gibbs, B. F., Schmelz, M., Homey, B., & Raap, U. (2018) · Der Hautarzt · doi:10.1007/s00105-018-4128-3 · Cited by 2
Self-citationAioi, A. (2020) · Trends in Immunotherapy · doi:10.24294/ti.v4.i2.1063 · Cited by 2
Izuhara, K., Nunomura, S., Ohta, S., Ogawa, M., & Nanri, Y. (2017) · Springer eBooks · doi:10.1007/978-981-10-5541-6_9 · Cited by 2
Nakahara, T., & Furue, M. (2018) · Current Treatment Options in Allergy · doi:10.1007/s40521-018-0191-3 · Cited by 2
Batbileg, L., Baasanjav, S., Tulgaa, K., Byambasukh, O., Nyamdavaa, K., Yadamsuren, E., & Biziya, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010112 · Cited by 1
Analysis of correlated factors of skin pruritus in type 2 diabetes mellitus
Cai, X., Tang, J., Yan, J., Shi, L., Xu, Y., & Tu, Y. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02120-x · Cited by 1
“Elevated levels of Th2 cytokines such as IL-4, IL-31, and IL-13 have been detected in the blood and/or skin lesions of patients with various pruritic conditions [41].”
Szepietowski, J. C., & Reszke, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-46352-0_6 · Cited by 1
Immunological Perspectives: Th2 Cells/Mast Cells/Basophils/Eosinophils
Hashimoto, T., & Satoh, T. (2017) · Springer eBooks · doi:10.1007/978-981-10-5541-6_7 · Cited by 1
Chronischer Pruritus: Epidemiologie, Diagnostik und Behandlung
Hoffmann, V., Pereira, M. P., & Ständer, S. (2019) · Aktuelle Dermatologie · doi:10.1055/a-0711-9717 · Cited by 1
Self-citation[ATOPIC DERMATITIS: ADVANCES IN UNDERSTANDING OF ITCH AND EFFICACY OF MOLECULAR TARGETED AGENTS].
Murota, H. (2019) · PubMed · doi:10.15036/arerugi.68.815 · Cited by 1
Staumont-Sallé, D., Barbarot, S., Bouaziz, J., Chan, C., Clibborn, C., Du-Thanh, A., Feeney, C., Lejeune, A., Misery, L., Nosbaum, A., et al. (2023) · JEADV Clinical Practice · doi:10.1002/jvc2.192 · Cited by 1
In Vitro Models of Filaggrin-Associated Diseases
Hedtrich, S. (2014) · Springer eBooks · doi:10.1007/978-3-642-54379-1_8 · Cited by 1
The Complexity of Pruritus Requires a Variety of Treatment Strategies
Meyer, N. H., Kotnik, N., Meyer, V., Gibbs, B. F., & Raap, U. (2019) · Current Treatment Options in Allergy · doi:10.1007/s40521-019-00217-y · Cited by 1
Self-citationDiversities of allergic pathologies and their modifiers: Report from the second DGAKI-JSA meeting
Asano, K., Tamari, M., Zuberbier, T., Yasudo, H., Morita, H., Fujieda, S., Nakamura, Y., Traidl, S., Hamelmann, E. H., Raap, U., et al. (2022) · Allergology International · doi:10.1016/j.alit.2022.05.003 · Cited by 1
Self-citationImmunology of Atopic Dermatitis
Byrne, A. M., & Leung, D. Y. M. (2011) · Harper's Textbook of Pediatric Dermatology · doi:10.1002/9781444345384.ch24 · Cited by 1
Can Lactobacillus Reuteri Prevent Allergic Disease in Early Childhood
Abrahamsson, T. (2009) · DiVA (Linkoping University) · Cited by 1
Reszke, R., & Szepietowski, J. C. (2019) · Wiley eBooks · doi:10.1002/9781119476009.ch13 · Cited by 1
Advances in Assessing the Severity of Atopic Dermatitis
Di, Z., Zhang, L., Lv, Y., Zhao, L., Chen, H., & Gao, X. (2012) · InTech eBooks · doi:10.5772/25596
“…al., 2011 Increase Ages ranged between 1 and 10 years (mean ± SD: 5.75 ± 2.11 years) Positive correlation with SCORAD index both in extrinsic AD and intrinsic AD Raap et al., 2008 Increase Extrinsic AD (mean age, 37.8±14.1 years); Intrinsic AD (mean age, 31.8±11.2…”
BackgroundInfluentialPathogeneseorientierte moderne Therapie der atopischen Dermatitis
Biedermann, T., & Werfel, T. (2015) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-014-3167-9
Self-citationNeuroimmunology and Itch of Atopic Dermatitis
Raap, U., & Kapp, A. (2011) · Pediatric and adolescent medicine · doi:10.1159/000328168
Self-citationIsmail, E. A., Ibrahim, H. A., Farid, C. I., Okasha, H. A. S., & Soliman, E. A. (2015) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.1097/01.ewx.0000452808.60760.71
Li, Q., Chung, H. J., Ross, N., Keller, M. D., Andrews, J., Kingman, J., Sarig, O., Fuchs‐Telem, D., Sprecher, E., Uitto, J., et al. (2015)
Mediators and receptors of chronic itch in primates and humans
Nattkemper, L. A. (2015) · TUScholarShare (Temple University)
Prurigo nodularis – an update on an important disease
Tsianakas, A., Zeidler, C., Riepe, C., & Ständer, S. (2016) · Journal of the Egyptian Womenʼs Dermatologic Society · doi:10.1097/01.ewx.0000481472.60356.9e
Self-citationSantoro, D. (2013) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Emerging Role of Tacrolimus in the Treatment of Atopic Dermatitis : Recent Advances
Nakahara, T., Morimoto, H., Murakami, N., & Furue, M. (2016) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.78.468
Systemic Therapy of Atopic Dermatitis: When, How, for How Long?
Malik, K., & Guttman‐Yassky, E. (2017) · Current Dermatology Reports · doi:10.1007/s13671-017-0176-7
Molecule guided laser ablation as a novel therapeutic strategy to control itchPreprint
Nocchi, L., D’Attilia, M., Roy, N., Dhandapani, R., Traista, A., Maffei, M., Castaldi, L., Perlas, E., & Heppenstall, P. A. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/225391
Therapie von chronischem Pruritus – was ist neu?
Zeidler, C., Metz, M., Steinke, S., & Ständer, S. (2018) · Der Hautarzt · doi:10.1007/s00105-018-4221-7
Self-citationCorrelation between Serum Interleukin-31 Level and the Severity of Atopic Dermatitis in Children
Atallah, R. B., Amer, A. W.-A., al-samee, H. A., & Ibraheem, R. M. (2019) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2019.22645
Traidl, S., Werfel, T., & Heratizadeh, A. (2019) · Der Deutsche Dermatologe · doi:10.1007/s15011-019-2485-6
Self-citationLee, K. H., & Park, C. O. (2021) · Springer eBooks · doi:10.1007/978-981-15-8159-5_13
Advances in the Translational Science of Dermatitis
Bilimoria, S. N., Tegtmeyer, K., & Lio, P. (2021) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.04.001
Nazzal, Z. A. S., Akkawi, A., Abdullah, I., Abdalkarim, M., Tayem, L., Khazneh, E., Taha, A. S. A., Basha, W., & Hamdan, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1519695/v1
山出史也 (2018) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.32.301
Aioi, A. (2019) · Trends in Immunotherapy · doi:10.24294/ti.v2.i3.1063
The Effect of Diet on ECP, IL-4 and IL-31 in Patients with Persistent Allergic Rhinitis
Yılmaz, Y. Z., Yılmaz, B. B., Yener, M., & Çanakçıoğlu, S. (2022) · Journal of Academic Research in Medicine · doi:10.4274/jarem.galenos.2022.54254
“IL-31 levels also correlate with the severity of the AR clinic (28,29).”
Malinow, I. K. (2022) · Springer eBooks · doi:10.1007/978-3-031-12867-7_14
Dupilumab for Recurrent Prurigo Nodularis: A Case Report and Review of the Literature
Jiang, W., Wang, X., Li, N., & Xu, Z. (2023) · MEDS Clinical Medicine · doi:10.23977/medsc.2023.040105
Neuroimmune Interactions in Acute and Chronic Itch
Ouyang, C., Rahman, S., Olexa, M., Ji, J., Huh, Y., & Ji, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-29231-6_7
Biologic drugs, a new therapeutic paradigm in moderate-severe atopic dermatitis
Vignoli, C. A., & Borroni, R. G. (2023) · doi:10.37349/eaa.2023.00020
Anti-IL-31 receptor alpha monoclonal antibody: Nemolizumab
Matsuzaki, H., & Odajima, H. (2023) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.37.497
Prurit et douleur cutanée au cours de la dermatite atopique
Misery, L. (2024) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/s2667-0623(24)00190-9
IL-31 suppresses the expression of TARC/CCL17 in TNF-alpha/IFN-gamma-stimulated HaCaT keratinocytesPreprint
Iwamoto, M., Takafuji, T., Yamada, Y., & Fujita, T. (2025) · Research Square · doi:10.21203/rs.3.rs-6260398/v1
Enigmatic Role of IL-31 in the Itch and Inflammation of Vernal Keratoconjunctivitis
Okamoto, M., Tominaga, M., Mashimo, K., Usui‐Ouchi, A., & Ebihara, N. (2026) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj25-0022-oa
Conservation of itch across species
Wheeler, J. J., & Mishra, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34172-4.00021-5
Rôle de l'oncostatine M et des interleukines 6 et 31 dans l'inflammation cutanée chez la souris
Pohin, M. (2017) · theses.fr (ABES) · doi:10.70675/6ee5de11z33c0z4d68z9887z2c7a7194291a
Metadata
- Authors
- Raap, U., Wichmann, K., Bruder, M., Ständer, S., Wedi, B., Kapp, A., & Werfel, T.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Münster (DE)
- Corresponding author
- Raap, Ulrike
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 122
- Issue
- 2
- Pages
- 421-423
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2083380164
- Cited by
- 299
- References
- 10
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 15 · 2023: 19 · 2022: 15 · 2021: 24 · 2020: 12 · 2019: 17 · 2018: 26 · 2017: 26 · 2016: 26 · 2015: 21 · 2014: 22 · 2013: 12 · 2012: 11
- FWCI
- 15.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Food Allergy and Anaphylaxis Network
- European Commission
- Astellas Pharma
- Medizinischen Hochschule Hannover
- UCB Pharma
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Keywords
- atopic dermatitis, IL-31, pruritus, disease severity, cytokines, scratching behavior, NC/Nga mice, T cells, quality of life, antipruritic therapy
- MeSH terms
- Adult, Dermatitis, Atopic, Humans, Interleukins, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
